Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-18-021474
Filing Date
2018-03-23
Accepted
2018-03-23 17:43:39
Documents
1
Period of Report
2018-03-23

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3244
  Complete submission text file 0001209191-18-021474.txt   4558
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2525 WEST END AVENUE, SUITE 950 NASHVILLE TN 37203
Business Address
Griggs Jonathan (Reporting) CIK: 0001490828 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33637 | Film No.: 18711206